WO2007031286A1 - Process for the preparation of an epoxy compound and an aldehyde - Google Patents

Process for the preparation of an epoxy compound and an aldehyde Download PDF

Info

Publication number
WO2007031286A1
WO2007031286A1 PCT/EP2006/008894 EP2006008894W WO2007031286A1 WO 2007031286 A1 WO2007031286 A1 WO 2007031286A1 EP 2006008894 W EP2006008894 W EP 2006008894W WO 2007031286 A1 WO2007031286 A1 WO 2007031286A1
Authority
WO
WIPO (PCT)
Prior art keywords
process according
ester
aldehyde
condensation step
ketone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/008894
Other languages
French (fr)
Inventor
Jochen Stangl
Claude Stritt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Priority to EP06805702A priority Critical patent/EP1945610B1/en
Priority to CN2006800340967A priority patent/CN101268044B/en
Priority to DE602006011932T priority patent/DE602006011932D1/en
Priority to AT06805702T priority patent/ATE455757T1/en
Priority to KR1020087006238A priority patent/KR101287303B1/en
Priority to US11/991,017 priority patent/US20090287006A1/en
Priority to JP2008530408A priority patent/JP5199096B2/en
Publication of WO2007031286A1 publication Critical patent/WO2007031286A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
    • C07C41/01—Preparation of ethers
    • C07C41/16—Preparation of ethers by reaction of esters of mineral or organic acids with hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D301/00—Preparation of oxiranes
    • C07D301/02—Synthesis of the oxirane ring
    • C07D301/24—Synthesis of the oxirane ring by splitting off HAL—Y from compounds containing the radical HAL—C—C—OY
    • C07D301/26—Y being hydrogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C403/00—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone
    • C07C403/14—Derivatives of cyclohexane or of a cyclohexene or of cyclohexadiene, having a side-chain containing an acyclic unsaturated part of at least four carbon atoms, this part being directly attached to the cyclohexane or cyclohexene or cyclohexadiene rings, e.g. vitamin A, beta-carotene, beta-ionone having side-chains substituted by doubly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/56—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds
    • C07C45/57—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom
    • C07C45/58—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds from heterocyclic compounds with oxygen as the only heteroatom in three-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Definitions

  • the invention relates to a process comprising a condensation step wherein a starting aldehyde or ketone is made to react with an ester of an ⁇ -haloacid to form an epoxy compound, in particular a glycidic ester.
  • 'Ci 4 aldehyde' refers to 2-methyl-4-(2,6,6-trimethyl-l-cyclohexene-l-yl)-2-butenal, an important intermediate in various processes such as the preparation of vitamin A, having the structural formula (I):
  • the Darzens condensation is carried out by creating a reaction mixture of ⁇ -ionone and an excess of a lower alkyl chloroacetate, e.g. methyl or ethyl chloroacetate.
  • ⁇ -ionone refers to 4-(2,6,6-trimethyl-l-cyclohexene- l-yl)-3-buten-2-one, a compound having formula (II):
  • an essentially anhydrous diluent is added; the diluent is in the known process chosen from the group consisting of dimethylformamide, pyridine, ⁇ -, ⁇ -, or ⁇ -picoline, dimethylacetamide and N-ethylacetamide.
  • This group of diluents comprises dipolar aprotic diluents.
  • a dry, alcohol-free alkali metal alkoxide is also added to the reaction mixture.
  • the reaction mixture is subsequently treated with cold methanolic sodium hydroxide at a low temperature, followed by recovery of the Ci 4 aldehyde. Recovery is in the known process typically done by pouring the reaction mixture into water, followed by extraction by an immiscible solvent such as hexane.
  • the known process has as disadvantage that a high amount of the compound acting as diluent should be used in order to achieve a high yield.
  • examples I and III of US 2,987,550 where a reduction of the molar ratio of the diluent dimethylformamide to ⁇ -ionone from about 2.2 in example I to about 1.1 in example III leads to a reduction of yield from 84.8% to 78%.
  • Example V In this example, a yield of 84.6 % was achieved; however, about 5 moles of the diluent pyridine was used per 1.1 1 mole of ⁇ -ionone, i.e. a ratio of about 4.5. Similar excess ratios of diluents are found in the other examples.
  • the condensation step is carried out in the presence of a dipolar aprotic compound selected from the group consisting of 1 -methyl-2- pyrrolidone (NMP), hexamethylfosforic acidtriamid (HMPT), dimethylsulfoxide (DMSO), and urea derivatives of the following formula (III):
  • NMP 1 -methyl-2- pyrrolidone
  • HMPT hexamethylfosforic acidtriamid
  • DMSO dimethylsulfoxide
  • Ri, R 2 , R 3 and R 4 may each independently be H or a Ci-C 4 alkyl group and whereby R 2 and R 3 may together form a heterocyclic group.
  • the process according to the invention has the advantage that very high selectivities and yields can be achieved without having to use high amounts - in relation to the starting aldehyde or ketone - of a further compound such as a compound acting as diluent.
  • a further advantage of the process according to the invention is that also the molar excess of the ester of ⁇ -haloacid - as compared to the starting aldehyde or ketone - can be reduced compared to the known process.
  • the dipolar aprotic compound selected according to the invention can have fewer or even no health- or environmental objections, and fewer objections regarding unpleasant odours, which is important because compounds such as the Cj 4 aldehyde are a.o. used in the preparation of perfumes.
  • CN 1348947 a process for the production of Ci 4 aldehyde from ⁇ -ionone via a Darzens condensation and using a solvent is disclosed.
  • the solvent should be a compound according to the formula (IV) as given below.
  • the process according to the invention comprises a condensation step.
  • a starting aldehyde or a starting ketone are present as raw material(s).
  • Aldhydes and ketones are as such known.
  • a wide variety of aldehydes or ketones may be used; preferably, they are aromatic.
  • An example of a starting ketone is ⁇ -ionone, the compound according to formula (II).
  • Further examples of preferred starting aldehydes or starting ketones are represented by formula (VII):
  • R 5 is preferably H - so that the compound according to formula (VII) is benzaldehyde - or CH 3 - so that the compound according to formula (VII) is acetophenone.
  • R. 5 may thus be H or CH 3 but also a C 2 - C 6 alkyl group.
  • an ester of an ⁇ -haloacid is also present.
  • the ester of an ⁇ -haloacid is methylchloroacetate, ethylchloroacetate, propylchloroacetate or butylchloroacetate; most preferably, the ester of an ⁇ -haloacid is methylchloroacetate.
  • the starting aldehyde or ketone and the ester of an ⁇ - haloacid are made to react with each other. This should be done in such a fashion - preferably by carrying out the reaction in the presence of a base - that an epoxy compound is formed.
  • epoxy compounds are characterised by the oxygen-containing three-membered ring as part of the compound.
  • glycidic esters can be formed in this fashion.
  • One known method of achieving this is via the known Darzens type of condensation reaction.
  • alkali metal alkoxide sodium methylate is preferred.
  • the 'alkoxide part' of the alkali metal alkoxide is preferably chosen so that it matches the 'ester part' of the ester of an ⁇ -haloacid (e.g., alkali metal methylate and the methyl ester of an ⁇ -haloacid such as chloroacetic acid); this has the advantage that the creation of a mixture of different alcohols is avoided.
  • an ⁇ -haloacid e.g., alkali metal methylate and the methyl ester of an ⁇ -haloacid such as chloroacetic acid
  • ⁇ -ionone is the starting ketone
  • methylchloroacetate is the ester of an ⁇ -haloacid
  • sodium methylate is the alkali metal alkoxide.
  • the glycidic ester thus formed has formula (V):
  • benzaldehyde - i.e. the compound according to formula (VII) with R 5 being H - is the starting aldehyde and a lower alkyl- (e.g. methyl- or ethyl-) chloroacetate is the ester of an ⁇ -haloacid.
  • the glycidic ester thus formed is ethyl 3-phenylglycidate, a compound according to formula (VIII):
  • acetophenone - i.e. the compound according to formula (VII) with R 5 being CH 3 - is the starting aldehyde and a lower alkyl (e.g. methyl- or ethyl-) chloroacetate is the ester of an ⁇ -haloacid.
  • the glycidic ester thus formed is ethyl 3-methyl-3-phenylglycidate, a compound according to formula (IX): HX
  • the condensation step is carried out in the presence of a further compound, not being the starting aldehyde or ketone, the ester of an ⁇ -haloacid or the alkali metal alkoxide.
  • the further compound is a dipolar aprotic compound or mixture of compounds selected from the group consisting of l-methyl-2-pyrrolidone (NMP), hexamethylfosforic acidtriamid (HMPT), dimethylsulfoxide (DMSO), and urea derivatives of the following formula:
  • Ri, R 2 , R 3 and R 4 may each independently be H or a Ci-C 4 alkyl group and whereby R 2 and R 3 may together form a heterocyclic group.
  • NMP l-methyl-2-pyrrolidone
  • Rj, R 2 , R 3 and R 4 are each independently H or a methyl or an ethyl group. In another embodiment, it is preferred that R], R 2 , R 3 and R 4 are identical.
  • R 2 and R 3 are such that compound (III) comprises a heterocyclic ring.
  • the term heterocyclic ring indicates a ring structure wherein the ring-forming atoms are not all carbon. Since R 2 and R 3 will in the case of ring-forming only contribute carbon atoms as ring- forming atoms, this implies that within the context of the present invention the two nitrogen atoms are comprised within the ring structure.
  • this ring is preferably a 5- or 6-ring.
  • Preferred examples of compounds according to formula (III) are urea, 1,3 -dimethyl tetrahydro-2( IH)- pyrimidinone (DMPU) or 1,1,3,3-tetramethylurea (TMU).
  • the dipolar aprotic compound as selected according to the invention does not need to be in liquid form, in particular not if the starting aldehyde or ketone and/or the ester of an ⁇ -haloacid are in liquid form; a liquid form is, nevertheless, preferred.
  • the condensation step is carried out in the presence of NMP.
  • the condensation step according to the invention it is an advantage of the condensation step according to the invention that high yields towards the epoxy compound such as a glycidic ester may be achieved with the utilisation of a relatively limited amount of the further compound such as NMP.
  • the molar ratio in the condensation step between the dipolar aprotic compound - as selected according to the invention - and the starting aldehyde or ketone lies between 0.05 and 2.
  • the said molar ratio is preferably higher than 0.05, so that the desired effect of yield enhancement is clearly noticeable. More preferably, the said ratio is at least 0.08, 0.10, 0.12, or 0.15.
  • the said molar ratio is preferably at most 2.00 so as to reap the maximum economical benefit from the condensation step according to the invention.
  • the said molar ratio is at most 1.90, 1.80, 1.75, 1.70, or 1.65. It is an advantage of the condensation step according to the invention that the molar excess of the ester of an ⁇ -haloacid - as compared to the starting aldehyde or ketone - can be reduced compared to the known process. This is particularly advantageous since this can be - and preferably is - combined with a low molar ratio between the dipolar aprotic compound as selected according to the invention and the starting aldehyde or ketone, as detailed above.
  • the molar ratio between the ester of an ⁇ -haloacid and the starting aldehyde or ketone lies between 1.00 and 2.00. More preferably, the said ratio is at least 1.05, 1.10, or 1.15, and at most 1.90, 1.80, or 1.70.
  • the condensation step according to the invention that the molar excess of the base such as the alkali metal alkoxide - as compared to the starting aldehyde or ketone - can be reduced compared to the known process.
  • This is particularly advantageous since this can be - and preferably is - combined with a low molar ratio between the dipolar aprotic compound as selected according to the invention and the starting aldehyde or ketone, as detailed above.
  • Even more advantageous is the preferred embodiment of also combining the low amount of alkali metal alkoxide with a low amount of an ester of an ⁇ -haloacid, according to the ranges as detailed above.
  • the molar ratio between the alkali metal alkoxide and the starting aldehyde or ketone lies between 1.00 and 2.00. More preferably, the said ratio is at least 1.05, 1.10, or 1.15, and at most 1.90, 1.80, or 1.70.
  • the condensation step according to the invention may typically be carried out at atmospheric pressures; there is usually not a ground to operate at reduced or increased pressures, although this is certainly possible should the characteristics of one of the compounds present require this according to the knowledge of those skilled in the art. It was found furthermore that it is often beneficial to carry out the condensation step according to the invention in a temperature range lying between -20°C and +10°C, as in this range both selectivity and yield are good. Within this range, the selectivity towards epoxy compound, in particular glycidic ester formation tends to increase as the temperature decreases. More preferably, the said temperature range goes from -15°C to +5°C.
  • the compounds designated as diluents or solvents in the known processes such as those of US 2,987,550 or CN 1348947 are present in only limited amounts, i.e. less than 50 wt.%, 40, 30, or even less than 10% compared to the amount of the dipolar aprotic compound selected according to the invention. More preferably, the said compounds according to the known processes are essentially absent.
  • the condensation step is followed by a saponification step.
  • the epoxy compound such as a glycidic ester as formed in the condensation step is saponified.
  • the said saponification may be achieved in a known fashion, e.g. by bringing the glycidic ester in contact with sodium hydroxide, whereby the said sodium hydroxide is typically anhydrous, and often dissolved in an alcohol such as methanol.
  • the saponification step is done on the glycidic ester according to formula (V).
  • the saponification step is followed by a hydrolysis step.
  • the saponified epoxy compound e.g., the saponified glycidic ester
  • the hydrolysis step is done on the glycidic ester according to formula (V) as saponified in the saponification step; the resulting aldehyde is then the Ci 4 aldehyde according to formula (I).
  • an aqueous system comprising water, the aldehyde or ketone as formed, and also the dipolar aprotic compound as selected according to the invention.
  • the aldehyde or ketone as formed may be recovered with methods known to the skilled person.
  • An example of such a method is an extraction step in which the aqueous system is brought in contact with an extracting agent, said extracting agent being limitedly or essentially non-miscible with water, and chosen such that the aldehyde or ketone migrates preferentially into the extracting agent.
  • extracting agents are alkanes such as hexane.
  • Example 1 The invention will be illustrated by means of the following examples, without being limited thereto.
  • Example 1 The invention will be illustrated by means of the following examples, without being limited thereto.
  • the molar ratio of NMP to ⁇ -ionone was 0.71 ; the molar ratio of methlychloroacetate to ⁇ - ionone was 1.23; the molar ratio of sodium methylate to ⁇ -ionone was 1.51.
  • Ci 4 aldehyde was then isolated through evaporation of the hexane under vacuum followed by distillation. A total of 205.6 g of the Ci 4 aldehyde was recovered, corresponding to a yield of 89.4% (calculated from the raw material ⁇ -ionone).
  • Example 1 The procedure of Example 1 was repeated, the only difference being the amount of NMP that was added. The results are given in the table below.
  • Example 1 The procedure of Example 1 was repeated; however, instead of NMP, DMPU was added in various amounts. The results are given in the table below.
  • Example 1 The procedure of Example 1 was repeated; however, instead of NMP, TMU was added in various amounts. The results are given in the table below.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)

Abstract

The invention relates to a process comprising a condensation step wherein a starting aldehyde or ketone is made to react with an ester of an α-haloacid to form an epoxy compound, whereby the reaction is carried out in the presence of a dipolar aprotic compound selected from the group consisting of l-methyl-2-pyrrolidone (NMP), hexamethylphosphorous triamide (HMPT), dimethylsulfoxide (DMSO), and urea derivatives of the following formula: (III) wherein R1, R2, R3 and R4 may each independently be H or a C1-C4 alkyl group and whereby R2 and R3 may together form a heterocyclic group.

Description

PROCESS FOR THE PREPARATION OF AN EPOXY COMPOUND AND AN
ALDEHYDE
The invention relates to a process comprising a condensation step wherein a starting aldehyde or ketone is made to react with an ester of an α-haloacid to form an epoxy compound, in particular a glycidic ester.
An example of such a process is a process comprising the known Darzens-type condensation reaction, discussed in for example US 2,987,550. In US 2,987,550 the Darzens preparation is disclosed as being a part of the preparation of the so-called 'Ci4 aldehyde'. In US 2,987,550 and also within the context of the present invention the term 'Ci4 aldehyde' refers to 2-methyl-4-(2,6,6-trimethyl-l-cyclohexene-l-yl)-2-butenal, an important intermediate in various processes such as the preparation of vitamin A, having the structural formula (I):
Figure imgf000002_0001
In the known process, the Darzens condensation is carried out by creating a reaction mixture of β-ionone and an excess of a lower alkyl chloroacetate, e.g. methyl or ethyl chloroacetate. As is known, the term β-ionone refers to 4-(2,6,6-trimethyl-l-cyclohexene- l-yl)-3-buten-2-one, a compound having formula (II):
Figure imgf000003_0001
During the mixing of the β-ionone with the alkyl chloroacetate in the known process, an essentially anhydrous diluent is added; the diluent is in the known process chosen from the group consisting of dimethylformamide, pyridine, α-, β-, or γ-picoline, dimethylacetamide and N-ethylacetamide. This group of diluents comprises dipolar aprotic diluents. A dry, alcohol-free alkali metal alkoxide is also added to the reaction mixture. The reaction mixture is subsequently treated with cold methanolic sodium hydroxide at a low temperature, followed by recovery of the Ci4 aldehyde. Recovery is in the known process typically done by pouring the reaction mixture into water, followed by extraction by an immiscible solvent such as hexane.
The known process has as disadvantage that a high amount of the compound acting as diluent should be used in order to achieve a high yield. As illustration of this, reference is made to examples I and III of US 2,987,550, where a reduction of the molar ratio of the diluent dimethylformamide to β-ionone from about 2.2 in example I to about 1.1 in example III leads to a reduction of yield from 84.8% to 78%. Furthermore, reference is made to Example V. In this example, a yield of 84.6 % was achieved; however, about 5 moles of the diluent pyridine was used per 1.1 1 mole of β-ionone, i.e. a ratio of about 4.5. Similar excess ratios of diluents are found in the other examples.
It is the objective of the present invention to reduce the disadvantage of the known process. The said objective is achieved in that the condensation step is carried out in the presence of a dipolar aprotic compound selected from the group consisting of 1 -methyl-2- pyrrolidone (NMP), hexamethylfosforic acidtriamid (HMPT), dimethylsulfoxide (DMSO), and urea derivatives of the following formula (III):
Figure imgf000004_0001
wherein Ri, R2, R3 and R4 may each independently be H or a Ci-C4 alkyl group and whereby R2 and R3 may together form a heterocyclic group.
The process according to the invention has the advantage that very high selectivities and yields can be achieved without having to use high amounts - in relation to the starting aldehyde or ketone - of a further compound such as a compound acting as diluent.
A further advantage of the process according to the invention is that also the molar excess of the ester of α-haloacid - as compared to the starting aldehyde or ketone - can be reduced compared to the known process.
Yet another advantage of the process according to the invention is that the dipolar aprotic compound selected according to the invention can have fewer or even no health- or environmental objections, and fewer objections regarding unpleasant odours, which is important because compounds such as the Cj4 aldehyde are a.o. used in the preparation of perfumes.
In CN 1348947, a process for the production of Ci4 aldehyde from β-ionone via a Darzens condensation and using a solvent is disclosed. According to CN 1348947, the solvent should be a compound according to the formula (IV) as given below.
Figure imgf000005_0001
(IV)
The process according to the invention comprises a condensation step. In this step, a starting aldehyde or a starting ketone are present as raw material(s). Aldhydes and ketones are as such known. In the process according to the invention, a wide variety of aldehydes or ketones may be used; preferably, they are aromatic. An example of a starting ketone is β-ionone, the compound according to formula (II). Further examples of preferred starting aldehydes or starting ketones are represented by formula (VII):
Figure imgf000005_0002
wherein R5 is preferably H - so that the compound according to formula (VII) is benzaldehyde - or CH3 - so that the compound according to formula (VII) is acetophenone. R.5 may thus be H or CH3 but also a C2 - C6 alkyl group.
In the condensation step, an ester of an α-haloacid is also present. Preferably, the ester of an α-haloacid is methylchloroacetate, ethylchloroacetate, propylchloroacetate or butylchloroacetate; most preferably, the ester of an α-haloacid is methylchloroacetate.
According to the invention, the starting aldehyde or ketone and the ester of an α- haloacid are made to react with each other. This should be done in such a fashion - preferably by carrying out the reaction in the presence of a base - that an epoxy compound is formed. As is known, epoxy compounds are characterised by the oxygen-containing three-membered ring as part of the compound. In particular, glycidic esters can be formed in this fashion. One known method of achieving this is via the known Darzens type of condensation reaction. As is known, in a Darzens condensation reaction the starting aldehyde or ketone is brought together with the ester of an α-haloacid; in order to make these react with each other, an alkali metal alkoxide (preferably dry and alcohol-free) is added as the base; in this fashion, the glycidic ester is formed. As alkali metal alkoxide, sodium methylate is preferred. Generally speaking, the 'alkoxide part' of the alkali metal alkoxide is preferably chosen so that it matches the 'ester part' of the ester of an α-haloacid (e.g., alkali metal methylate and the methyl ester of an α-haloacid such as chloroacetic acid); this has the advantage that the creation of a mixture of different alcohols is avoided.
In a preferred embodiment of the condensation step, β-ionone is the starting ketone, methylchloroacetate is the ester of an α-haloacid and sodium methylate is the alkali metal alkoxide. The glycidic ester thus formed has formula (V):
Figure imgf000006_0001
In another preferred embodiment of the condensation step, benzaldehyde - i.e. the compound according to formula (VII) with R5 being H - is the starting aldehyde and a lower alkyl- (e.g. methyl- or ethyl-) chloroacetate is the ester of an α-haloacid. The glycidic ester thus formed is ethyl 3-phenylglycidate, a compound according to formula (VIII):
Figure imgf000006_0002
In a further preferred embodiment of the condensation step, acetophenone - i.e. the compound according to formula (VII) with R5 being CH3 - is the starting aldehyde and a lower alkyl (e.g. methyl- or ethyl-) chloroacetate is the ester of an α-haloacid. The glycidic ester thus formed is ethyl 3-methyl-3-phenylglycidate, a compound according to formula (IX): HX
Figure imgf000007_0001
The compounds according to formulas (VIII) and (IX) are as such known, from e.g. section 2.7.3 of the Flavors and Fragrances chapter of Ullmann's Encyclopedia of Industrial Chemistry, DOI 10.1002/14356007.al l 141, posted online on 15.01.2003.
According to the invention, the condensation step is carried out in the presence of a further compound, not being the starting aldehyde or ketone, the ester of an α-haloacid or the alkali metal alkoxide. In contrast to the known process where the said further compound is chosen from the group as detailed in the discussion above on the known process, the further compound is a dipolar aprotic compound or mixture of compounds selected from the group consisting of l-methyl-2-pyrrolidone (NMP), hexamethylfosforic acidtriamid (HMPT), dimethylsulfoxide (DMSO), and urea derivatives of the following formula:
Figure imgf000007_0002
wherein Ri, R2, R3 and R4 may each independently be H or a Ci-C4 alkyl group and whereby R2 and R3 may together form a heterocyclic group. Without committing to scientific theory, it is thought that the further compound according to the invention does not significantly react during the condensation step, but rather may act as diluent and/or as solvent and/or as heat transfer medium and/or in yet another fashion.
As is known, the compound l-methyl-2-pyrrolidone (NMP) has formula (VI).
Figure imgf000008_0001
In formula (III), it is preferred that Rj, R2, R3 and R4 are each independently H or a methyl or an ethyl group. In another embodiment, it is preferred that R], R2, R3 and R4 are identical. In another class of preferred embodiments of the compound according to formula (III), R2 and R3 are such that compound (III) comprises a heterocyclic ring. As is known, the term heterocyclic ring indicates a ring structure wherein the ring-forming atoms are not all carbon. Since R2 and R3 will in the case of ring-forming only contribute carbon atoms as ring- forming atoms, this implies that within the context of the present invention the two nitrogen atoms are comprised within the ring structure. If the compound according to formula (III) has a heterocyclic ring, then this ring is preferably a 5- or 6-ring. Preferred examples of compounds according to formula (III) are urea, 1,3 -dimethyl tetrahydro-2( IH)- pyrimidinone (DMPU) or 1,1,3,3-tetramethylurea (TMU).
The dipolar aprotic compound as selected according to the invention does not need to be in liquid form, in particular not if the starting aldehyde or ketone and/or the ester of an α-haloacid are in liquid form; a liquid form is, nevertheless, preferred. Most preferably, the condensation step is carried out in the presence of NMP.
It is an advantage of the condensation step according to the invention that high yields towards the epoxy compound such as a glycidic ester may be achieved with the utilisation of a relatively limited amount of the further compound such as NMP. It is preferred that the molar ratio in the condensation step between the dipolar aprotic compound - as selected according to the invention - and the starting aldehyde or ketone lies between 0.05 and 2. The said molar ratio is preferably higher than 0.05, so that the desired effect of yield enhancement is clearly noticeable. More preferably, the said ratio is at least 0.08, 0.10, 0.12, or 0.15. The said molar ratio is preferably at most 2.00 so as to reap the maximum economical benefit from the condensation step according to the invention. More preferably, the said molar ratio is at most 1.90, 1.80, 1.75, 1.70, or 1.65. It is an advantage of the condensation step according to the invention that the molar excess of the ester of an α-haloacid - as compared to the starting aldehyde or ketone - can be reduced compared to the known process. This is particularly advantageous since this can be - and preferably is - combined with a low molar ratio between the dipolar aprotic compound as selected according to the invention and the starting aldehyde or ketone, as detailed above. Preferably, the molar ratio between the ester of an α-haloacid and the starting aldehyde or ketone lies between 1.00 and 2.00. More preferably, the said ratio is at least 1.05, 1.10, or 1.15, and at most 1.90, 1.80, or 1.70.
It is a further advantage of the condensation step according to the invention that the molar excess of the base such as the alkali metal alkoxide - as compared to the starting aldehyde or ketone - can be reduced compared to the known process. This is particularly advantageous since this can be - and preferably is - combined with a low molar ratio between the dipolar aprotic compound as selected according to the invention and the starting aldehyde or ketone, as detailed above. Even more advantageous is the preferred embodiment of also combining the low amount of alkali metal alkoxide with a low amount of an ester of an α-haloacid, according to the ranges as detailed above. Preferably, the molar ratio between the alkali metal alkoxide and the starting aldehyde or ketone lies between 1.00 and 2.00. More preferably, the said ratio is at least 1.05, 1.10, or 1.15, and at most 1.90, 1.80, or 1.70.
The condensation step according to the invention may typically be carried out at atmospheric pressures; there is usually not a ground to operate at reduced or increased pressures, although this is certainly possible should the characteristics of one of the compounds present require this according to the knowledge of those skilled in the art. It was found furthermore that it is often beneficial to carry out the condensation step according to the invention in a temperature range lying between -20°C and +10°C, as in this range both selectivity and yield are good. Within this range, the selectivity towards epoxy compound, in particular glycidic ester formation tends to increase as the temperature decreases. More preferably, the said temperature range goes from -15°C to +5°C.
It is preferred that in the condensation step according to the invention the compounds designated as diluents or solvents in the known processes such as those of US 2,987,550 or CN 1348947 are present in only limited amounts, i.e. less than 50 wt.%, 40, 30, or even less than 10% compared to the amount of the dipolar aprotic compound selected according to the invention. More preferably, the said compounds according to the known processes are essentially absent.
In practice and preferred according to the present invention, the condensation step is followed by a saponification step. In the saponification step, the principle of which is as such known, the epoxy compound such as a glycidic ester as formed in the condensation step is saponified. The said saponification may be achieved in a known fashion, e.g. by bringing the glycidic ester in contact with sodium hydroxide, whereby the said sodium hydroxide is typically anhydrous, and often dissolved in an alcohol such as methanol. According to a preferred embodiment according to the invention, the saponification step is done on the glycidic ester according to formula (V).
In practice and also preferred according to the present invention, the saponification step is followed by a hydrolysis step. In this step, the saponified epoxy compound (e.g., the saponified glycidic ester) is brought into contact with an aqueous phase; this leads to decarboxylation of the saponified epoxy compound or glycidic ester, whereby an aldehyde or ketone is formed. According to a preferred embodiment according to the invention, the hydrolysis step is done on the glycidic ester according to formula (V) as saponified in the saponification step; the resulting aldehyde is then the Ci4 aldehyde according to formula (I).
Upon completion of the hydrolysis step, an aqueous system is present comprising water, the aldehyde or ketone as formed, and also the dipolar aprotic compound as selected according to the invention. The aldehyde or ketone as formed may be recovered with methods known to the skilled person. An example of such a method is an extraction step in which the aqueous system is brought in contact with an extracting agent, said extracting agent being limitedly or essentially non-miscible with water, and chosen such that the aldehyde or ketone migrates preferentially into the extracting agent. Examples of extracting agents are alkanes such as hexane.
The invention will be illustrated by means of the following examples, without being limited thereto. Example 1
β-ionone (212.7 g, 97% purity, 1.07 moles), methylchloroacetate (146.4 g, 1.35 moles) and NMP (75 g, 0.76 moles) were put into a stirred reactor and cooled to 0°C. Sodium methylate (87.6 g, 1.62 moles) was then dosed, leading to the reaction to the corresponding glycid ester. After the sodium methylate had been added, the reactor contents were brought to 20°C and remained there for 20 minutes. In this Example, the molar ratio of NMP to β-ionone was 0.71 ; the molar ratio of methlychloroacetate to β- ionone was 1.23; the molar ratio of sodium methylate to β-ionone was 1.51.
Subsequent to the formation of the glycidic ester, saponification was achieved through addition of sodium hydroxide, whereby the temperature rose to 35°C. The reaction mixture was then transferred to a second stirred vessel; in the said second stirred vessel, the hydrolysis reaction to the Ci4 aldehyde was done by means of addition of water. Then, hexane was added to the reaction mixture - while being stirred. This lead to the extraction of the C)4 aldehyde from the aqueous mixture into the hexane phase. The hexane phase was separated from the aqueous phase and acidified through the addition of some aqueous acetic acid. The Ci4 aldehyde was then isolated through evaporation of the hexane under vacuum followed by distillation. A total of 205.6 g of the Ci4 aldehyde was recovered, corresponding to a yield of 89.4% (calculated from the raw material β-ionone).
Examples 2 - 5
The procedure of Example 1 was repeated, the only difference being the amount of NMP that was added. The results are given in the table below.
Figure imgf000012_0001
Examples 6 - 10
The procedure of Example 1 was repeated; however, instead of NMP, DMPU was added in various amounts. The results are given in the table below.
Figure imgf000012_0002
Examples 1 1-15
The procedure of Example 1 was repeated; however, instead of NMP, TMU was added in various amounts. The results are given in the table below.
Figure imgf000013_0001

Claims

Claims
1. Process comprising a condensation step wherein a starting aldehyde or ketone is made to react with an ester of an α-haloacid to form an epoxy compound, whereby the reaction is carried out in the presence of a dipolar aprotic compound selected from the group consisting of 1 -methyl-2-pyrrolidone (NMP), hexamethylphosphorous triamide (HMPT), dimethylsulfoxide (DMSO), and urea derivatives of the following formula:
R2 R3
. N N.
R1" R4
O
(III)
wherein Ri, R2, R3 and R4 may each independently be H or a Ci-C4 alkyl group and whereby R2 and R3 may together form a heterocyclic group.
2. Process according to claim 1 , wherein the condensation step is carried out in the presence of a base.
3. Process according to claim 2, wherein the base is an alkali metal alkoxide.
4. Process according to any one of claims 1 - 3, wherein the epoxy compound is a glycidic ester, and wherein the process further comprises a saponification step, wherein the glycidic ester is saponified, and a hydrolysis step, wherein the saponified glycidic ester is decarboxylated to form an aldehyde.
5. Process according to any one of claims 1 - 4, wherein the raw materials for the condensation step comprise β-ionone.
6. Process according to claim 4, wherein the raw materials for the condensation step comprise β-ionone, methylchloroacetate, sodium methylate and l-methyl-2- pyrrolidon (NMP), and whereby in the hydrolysis step the Ci4 aldehyde 2-methyl-4- (2,6,6-trimethyl-l-cyclohexene-l-yl)-2-butenal is formed.
7. Process according to any one of claims 1 - 3, wherein the raw materials for the condensation step comprise benzaldehyde and/or acetophenone.
8. Process according to any one of claims 1 - 7, wherein the molar ratio in the condensation step between the dipolar aprotic compound and the starting aldehyde or ketone lies between 0.05 and 2.
9. Process according to any one of claims 1 - 8, wherein the molar ratio in the condensation step between the ester of an α-haloacid and the starting aldehyde or ketone lies between 1.0 and 2.0.
10. Process according to any one of claims 3 - 9, wherein the molar ratio in the condensation step between the alkali metal alkoxide and the starting aldehyde or ketone lies between 1.0 and 2.0.
1 1. Process according to claim 1 , wherein the dipolar aprotic compound is according to formula (III) and is l,3-dimethyltetrahydro-2(lH)-pyrimidinone (DMPU) or 1,1,3,3- tetramethylurea (TMU).
12. Process for the preparation of vitamin A or an ester of vitamin A, characterised in that the process comprises the process according to anyone of claims 1 - 8.
***
PCT/EP2006/008894 2005-09-16 2006-09-13 Process for the preparation of an epoxy compound and an aldehyde Ceased WO2007031286A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP06805702A EP1945610B1 (en) 2005-09-16 2006-09-13 Process for the preparation of an epoxy compound and an aldehyde
CN2006800340967A CN101268044B (en) 2005-09-16 2006-09-13 Process for the preparation of an epoxy compound and an aldehyde
DE602006011932T DE602006011932D1 (en) 2005-09-16 2006-09-13 PROCESS FOR PREPARING AN EPOXY COMPOUND AND AN ALDEHYDE
AT06805702T ATE455757T1 (en) 2005-09-16 2006-09-13 METHOD FOR PRODUCING AN EPOXY COMPOUND AND AN ALDEHYDE
KR1020087006238A KR101287303B1 (en) 2005-09-16 2006-09-13 Process for the preparation of an epoxy compound and an aldehyde
US11/991,017 US20090287006A1 (en) 2005-09-16 2006-09-13 Process for the preparation of an epoxy compound and an aldehyde
JP2008530408A JP5199096B2 (en) 2005-09-16 2006-09-13 Preparation method of epoxy compound and aldehyde

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05020206A EP1764359A1 (en) 2005-09-16 2005-09-16 Process for the preparation of glycidic ester and an aldehyde
EP05020206.8 2005-09-16

Publications (1)

Publication Number Publication Date
WO2007031286A1 true WO2007031286A1 (en) 2007-03-22

Family

ID=35840036

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/008894 Ceased WO2007031286A1 (en) 2005-09-16 2006-09-13 Process for the preparation of an epoxy compound and an aldehyde

Country Status (8)

Country Link
US (1) US20090287006A1 (en)
EP (2) EP1764359A1 (en)
JP (1) JP5199096B2 (en)
KR (1) KR101287303B1 (en)
CN (1) CN101268044B (en)
AT (1) ATE455757T1 (en)
DE (1) DE602006011932D1 (en)
WO (1) WO2007031286A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1800727A1 (en) * 2005-12-20 2007-06-27 DSMIP Assets B.V. Process for the treatment of an aqueous mixture comprising a dipolar aprotic compound
CN105439838B (en) * 2014-09-19 2017-12-01 上虞新和成生物化工有限公司 The preparation method of the aldehyde of 2 methyl 4 (base of 2,6,6 trimethyl, 1 cyclohexene 1) 2 butylene 1
CN106045829B (en) * 2016-06-06 2018-09-14 上虞新和成生物化工有限公司 A kind of epoxy carboxylic acids' ester prepares the green synthesis process of 2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-butenal
WO2018069452A1 (en) * 2016-10-12 2018-04-19 Dsm Ip Assets B.V. Process for the manufacture of a mixture of 2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-butenal and 2-methyl-4-(2,6,6-trimethyl-2-cyclohexen-1-yl)-2-butenal
JP7298088B2 (en) * 2018-04-11 2023-06-27 ディーエスエム アイピー アセッツ ビー.ブイ. Process for producing 2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-butenal

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2987550A (en) * 1958-09-25 1961-06-06 Pfizer & Co C Process for the manufacture of c14 aldehyde
EP0371264A2 (en) * 1988-10-31 1990-06-06 Loyola University Of Chicago Phosphonate reagent compositions and methods of making same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3933864A (en) * 1974-12-10 1976-01-20 The Upjohn Company Process for preparing glycidonitriles
US4499294A (en) * 1983-01-21 1985-02-12 Mcneilab, Inc. Process for production of methyl 2-tetradecylgycidate
JPH0272168A (en) * 1988-09-07 1990-03-12 Inoue Koryo Seizosho:Kk Perfume composition and production of alpha-alkyl substituted-beta-methyl-beta-phenylglycidic acid ester
JP2986003B2 (en) * 1993-11-05 1999-12-06 宇部興産株式会社 2-Alkyl-3-styryloxiranecarboxylic acid ester and method for producing the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2987550A (en) * 1958-09-25 1961-06-06 Pfizer & Co C Process for the manufacture of c14 aldehyde
EP0371264A2 (en) * 1988-10-31 1990-06-06 Loyola University Of Chicago Phosphonate reagent compositions and methods of making same

Also Published As

Publication number Publication date
CN101268044B (en) 2011-07-06
EP1764359A1 (en) 2007-03-21
JP5199096B2 (en) 2013-05-15
ATE455757T1 (en) 2010-02-15
US20090287006A1 (en) 2009-11-19
EP1945610B1 (en) 2010-01-20
EP1945610A1 (en) 2008-07-23
KR101287303B1 (en) 2013-07-17
CN101268044A (en) 2008-09-17
DE602006011932D1 (en) 2010-03-11
JP2009512630A (en) 2009-03-26
KR20080044876A (en) 2008-05-21

Similar Documents

Publication Publication Date Title
US7141698B2 (en) Continuous process for producing pseudoionones and ionones
EP1945610B1 (en) Process for the preparation of an epoxy compound and an aldehyde
JPH0157102B2 (en)
CN101573318A (en) Process for the preparation of belta-ionones and vitamin A, vitamin A derivatives, carotenes and carotenoids
CH631151A5 (en) PROCESS FOR THE PREPARATION OF HEMACETAL-ESTERS OF GLYOXYLIC ACID.
JPH1180149A (en) Optical resolution of (±) -chromancarboxylic acid
CN113336629A (en) Preparation process of 1,3 cyclohexanedione
CN112645799A (en) Resorcinol post-treatment process
EP0013995B1 (en) Process for the preparation of acetylenic macrocyclic ketones
FR2557098A1 (en) PROCESS FOR THE PREPARATION OF SUBSTITUTED HYDROXY AND / OR ALKOXY BROMOBENZALDEHYDES
JP2011105762A (en) Method for preparing 1-hydroperoxy-16-oxabicyclo[10.4.0]hexadecane
JPH0273033A (en) Production of 4, 4-dimethyl-1-(p-chlorophenyl) pentane-3-one
JP7298088B2 (en) Process for producing 2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2-butenal
JP6801930B2 (en) Process for the preparation of diaminobutane
HU192144B (en) Process for preparing 2,2-dimethyl-3-aryl-cyclopropane-carboxylic acid derivatives
CN113666814B (en) Synthesis method of high-purity raspberry ketone
RU2236397C1 (en) Method for preparing 2,3,4-trimethoxybenaldehyde
JPH10182539A (en) Production of o-phthalaldehyde glutaraldehyde aqueous solution
EP0019531B1 (en) Crystallised sodium paraformyl phenolate, process for its preparation and its application
CN109096047B (en) Preparation method of (1R) -1, 3-diphenyl-1-propanol
JPS6326106B2 (en)
JP2732904B2 (en) Separation method of cyclohexanol
KR100530345B1 (en) Method for preparing amine compound from nitro compound using indium metal wire
JPS6039183A (en) Manufacture of terephthalaldehyde
JPH0920717A (en) Production of arylidene-substituted alkyl-cycloalkanone

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006805702

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1316/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020087006238

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2008530408

Country of ref document: JP

Ref document number: 200680034096.7

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 11991017

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2006805702

Country of ref document: EP